Comments
The US Food and Drug Administration (USFDA) has cleared pharma major Dr Reddy’s Laboratories Ltd’s formulation Srikakulam Plant (SEZ) Unit I in Andhra Pradesh from its recent audit.
The Hyderabad-based company had received an Establishment Inspection Report (EIR) from the USFDA for the above-referred facility, the Bombay Stock Exchange was informed on Thursday.
“With regard to the audit of the company’s formulation Srikakulam Plant (SEZ) Unit I, Andhra Pradesh...the company has received an EIR from USFDA, for the above-referred facility,” Dr Reddy’s said in a regulatory filing today.
USFDA issues an EIR to the establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection.
The stock gained 4.46 per cent to Rs 2,410.55 on the BSE. On the NSE, shares of the company jumped 4.67 per cent to Rs 2,412.40. The stock was the top gainer on both the key indices during the morning trade.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.